Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NASDAQ:CORT
- CUSIP: 21835210
- Web: www.corcept.com
Capitalization:- Market Cap: $2.08992 billion
- Outstanding Shares: 113,397,000
Average Prices:- 50 Day Moving Avg: $15.54
- 200 Day Moving Avg: $12.18
- 52 Week Range: $5.85 - $18.54
P/E:- Trailing P/E Ratio: 89.45
- Foreward P/E Ratio: 24.97
- P/E Growth: 0.59
Sales & Book Value:- Annual Revenue: $108.69 million
- Price / Sales: 18.76
- Book Value: $0.58 per share
- Price / Book: 31.00
Profitability:- EBIDTA: $25.67 million
- Net Margins: 22.28%
- Return on Equity: 51.45%
- Return on Assets: 33.01%
Debt:- Current Ratio: 3.99%
- Quick Ratio: 3.84%
Misc:- Average Volume: 1.13 million shs.
- Beta: 2.07
- Short Ratio: 10.59
Frequently Asked Questions for Corcept Therapeutics Incorporated (NASDAQ:CORT)
What is Corcept Therapeutics Incorporated's stock symbol?
Corcept Therapeutics Incorporated trades on the NASDAQ under the ticker symbol "CORT."
How were Corcept Therapeutics Incorporated's earnings last quarter?
Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Tuesday, August, 1st. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.02. The firm had revenue of $35.56 million for the quarter, compared to the consensus estimate of $31.37 million. Corcept Therapeutics Incorporated had a return on equity of 51.45% and a net margin of 22.28%. The firm's revenue for the quarter was up 80.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.01 EPS. View Corcept Therapeutics Incorporated's Earnings History.
When will Corcept Therapeutics Incorporated make its next earnings announcement?
Where is Corcept Therapeutics Incorporated's stock going? Where will Corcept Therapeutics Incorporated's stock price be in 2017?
5 brokers have issued twelve-month target prices for Corcept Therapeutics Incorporated's stock. Their predictions range from $7.00 to $24.00. On average, they expect Corcept Therapeutics Incorporated's share price to reach $16.60 in the next twelve months. View Analyst Ratings for Corcept Therapeutics Incorporated.
Who are some of Corcept Therapeutics Incorporated's key competitors?
Some companies that are related to Corcept Therapeutics Incorporated include Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD), Horizon Pharma PLC (HZNP), Cambrex Corporation (CBM), Theravance Biopharma (TBPH), AKCEA THERAPEUT (AKCA), Emergent Biosolutions (EBS), Impax Laboratories (IPXL), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), Amphastar Pharmaceuticals (AMPH), AMAG Pharmaceuticals (AMAG), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN) and Teligent (TLGT).
Who are Corcept Therapeutics Incorporated's key executives?
Corcept Therapeutics Incorporated's management team includes the folowing people:
- James N. Wilson, Independent Chairman of the Board
- Joseph K. Belanoff M.D., President, Chief Executive Officer, Director
- Gary Charles Robb, Chief Financial Officer, Secretary
- Robert S. Fishman M.D., Chief Medical Officer
- G. Leonard Baker Jr., Independent Director
- Daniel M. Bradbury, Independent Director
- Renee D. Gala, Independent Director
- David L. Mahoney, Independent Director
- Daniel N. Swisher Jr., Independent Director
Who owns Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Federated Investors Inc. PA (12.49%), Ingalls & Snyder LLC (6.46%), Vanguard Group Inc. (3.92%), Renaissance Technologies LLC (2.37%), State Street Corp (1.79%) and Acadian Asset Management LLC (1.50%). Company insiders that own Corcept Therapeutics Incorporated stock include Daniel Bradbury, David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, James N Wilson, Joseph K Belanoff, Patrick G Enright and Steven Lo. View Institutional Ownership Trends for Corcept Therapeutics Incorporated.
Who sold Corcept Therapeutics Incorporated stock? Who is selling Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC, Federated Investors Inc. PA, Lord Abbett & CO. LLC, GSA Capital Partners LLP, Menta Capital LLC, Arrowstreet Capital Limited Partnership, Wells Fargo & Company MN and Numeric Investors LLC. Company insiders that have sold Corcept Therapeutics Incorporated stock in the last year include David L Mahoney, James N Wilson, Joseph K Belanoff and Patrick G Enright. View Insider Buying and Selling for Corcept Therapeutics Incorporated.
Who bought Corcept Therapeutics Incorporated stock? Who is buying Corcept Therapeutics Incorporated stock?
Corcept Therapeutics Incorporated's stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Renaissance Technologies LLC, Vanguard Group Inc., Teachers Advisors LLC, Prudential Financial Inc., Acadian Asset Management LLC, Russell Investments Group Ltd. and State Street Corp. Company insiders that have bought Corcept Therapeutics Incorporated stock in the last two years include G Leonard Baker Jr and Gary Charles Robb. View Insider Buying and Selling for Corcept Therapeutics Incorporated.
How do I buy Corcept Therapeutics Incorporated stock?
Shares of Corcept Therapeutics Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corcept Therapeutics Incorporated's stock price today?
One share of Corcept Therapeutics Incorporated stock can currently be purchased for approximately $17.98.
MarketBeat Community Rating for Corcept Therapeutics Incorporated (NASDAQ CORT)MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Corcept Therapeutics Incorporated (NASDAQ:CORT) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $16.60 (7.68% downside) |
Analysts' Ratings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/8/2017 | Piper Jaffray Companies | Boost Price Target | Buy | $18.00 -> $24.00 | Low |  |
| 8/31/2017 | Stifel Nicolaus | Initiated Coverage | Buy -> Buy | $20.00 | High | |
| 7/18/2017 | Ladenburg Thalmann Financial Services | Set Price Target | Buy | $15.00 -> $20.00 | Low | |
| 12/20/2016 | Janney Montgomery Scott | Initiated Coverage | Sell | $7.00 | N/A | |
| 11/2/2016 | FBR & Co | Set Price Target | Buy | $12.00 | N/A | |
(Data available from 9/20/2015 forward)
Earnings History for Corcept Therapeutics Incorporated (NASDAQ:CORT)Earnings History by Quarter for Corcept Therapeutics Incorporated (NASDAQ CORT)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/30/2017 | | $0.09 | | | | | N/A | |
| 8/1/2017 | Q2 2017 | $0.08 | $0.10 | $31.37 million | $35.56 million | View | N/A | |
| 5/1/2017 | Q1 2017 | $0.03 | $0.04 | $25.53 million | $27.60 million | View | Listen | |
| 3/6/2017 | Q4 2016 | $0.04 | $0.04 | $23.85 million | $23.81 million | View | N/A | |
| 11/1/2016 | Q316 | $0.01 | $0.02 | $21.24 million | $21.70 million | View | N/A | |
| 1/28/2016 | Q415 | ($0.02) | $0.01 | $15.50 million | $15.00 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.02) | ($0.01) | $13.90 million | $13.30 million | View | N/A | |
| 8/5/2015 | Q215 | ($0.04) | ($0.02) | $11.67 million | $11.96 million | View | N/A | |
| 5/7/2015 | Q115 | ($0.04) | ($0.05) | $10.50 million | $10.10 million | View | N/A | |
| 3/4/2015 | Q414 | ($0.06) | ($0.03) | $9.10 million | $9.01 million | View | N/A | |
| 11/4/2014 | Q214 | ($0.07) | ($0.05) | $7.62 million | $7.28 million | View | N/A | |
| 5/7/2014 | Q114 | ($0.10) | ($0.13) | $5.01 million | $4.41 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.10) | ($0.11) | $4.01 million | $4.10 million | View | N/A | |
| 1/30/2014 | Q4 | ($0.12) | ($0.10) | | | View | N/A | |
| 11/7/2013 | Q313 | ($0.12) | ($0.08) | $2.70 million | $2.60 million | View | N/A | |
| 8/8/2013 | Q2 2013 | ($0.11) | ($0.10) | $2.72 million | $1.90 million | View | N/A | |
| 5/2/2013 | Q1 2013 | ($0.09) | ($0.10) | $2.48 million | $1.72 million | View | N/A | |
| 3/7/2013 | Q4 2012 | ($0.09) | ($0.09) | $1.50 million | $1.38 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)Current Year EPS Consensus Estimate: $0.42 EPS
Next Year EPS Consensus Estimate: $0.72 EPS
Dividend History for Corcept Therapeutics Incorporated (NASDAQ:CORT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Corcept Therapeutics Incorporated (NASDAQ:CORT)Insider Ownership Percentage: 19.20%
Institutional Ownership Percentage: 61.48%
Insider Trades by Quarter for Corcept Therapeutics Incorporated (NASDAQ:CORT)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/19/2017 | David L Mahoney | Director | Sell | 23,006 | $12.50 | $287,575.00 | |
| 7/18/2017 | David L Mahoney | Director | Sell | 6,091 | $12.50 | $76,137.50 | |
| 7/13/2017 | David L Mahoney | Director | Sell | 6,994 | $12.50 | $87,425.00 | |
| 7/12/2017 | David L Mahoney | Director | Sell | 6,510 | $12.50 | $81,375.00 | |
| 5/4/2017 | Gary Charles Robb | CFO | Buy | 5,600 | $9.75 | $54,600.00 | |
| 3/16/2017 | Patrick G. Enright | Director | Sell | 269,955 | $9.94 | $2,683,352.70 | |
| 3/15/2017 | Patrick G Enright | Director | Sell | 600,000 | $10.15 | $6,090,000.00 | |
| 3/8/2017 | Patrick G Enright | Director | Sell | 750,000 | $9.75 | $7,312,500.00 | |
| 2/27/2017 | Patrick G Enright | Director | Sell | 2,500,000 | $8.81 | $22,025,000.00 | |
| 11/25/2016 | Patrick G Enright | Director | Sell | 36,941 | $9.34 | $345,028.94 | |
| 11/21/2016 | Patrick G Enright | Director | Sell | 544,100 | $9.56 | $5,201,596.00 | |
| 11/16/2016 | Patrick G Enright | Director | Sell | 174,847 | $9.55 | $1,669,788.85 | |
| 11/11/2016 | James N Wilson | Director | Sell | 158,812 | $8.51 | $1,351,490.12 | |
| 11/11/2016 | Joseph K Belanoff | Insider | Sell | 500,000 | $8.98 | $4,490,000.00 | |
| 11/7/2016 | Joseph K Belanoff | CEO | Sell | 500,000 | $8.31 | $4,155,000.00 | |
| 5/10/2016 | G Leonard Baker Jr | Director | Buy | 100,000 | $4.88 | $488,000.00 | |
| 1/6/2016 | James N Wilson | Director | Sell | 1,188 | $4.90 | $5,821.20 | |
| 12/10/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.85 | $97,000.00 | |
| 11/24/2015 | Daniel Bradbury | Director | Sell | 40,000 | $5.00 | $200,000.00 | |
| 11/12/2015 | James N Wilson | Director | Sell | 20,000 | $4.90 | $98,000.00 | |
| 11/2/2015 | Steven Lo | VP | Sell | 12,500 | $4.00 | $50,000.00 | |
| 10/13/2015 | Steven Lo | VP | Sell | 53,033 | $3.82 | $202,586.06 | |
| 10/7/2015 | Steven Lo | VP | Sell | 5,300 | $4.00 | $21,200.00 | |
| 10/6/2015 | Steven Lo | VP | Sell | 50,000 | $3.76 | $188,000.00 | |
| 9/16/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.96 | $99,200.00 | |
| 9/1/2015 | James N Wilson | Director | Sell | 10,000 | $4.90 | $49,000.00 | |
| 8/27/2015 | Daniel Bradbury | Director | Sell | 20,000 | $4.76 | $95,200.00 | |
| 7/21/2015 | Daniel Bradbury | Director | Sell | 10,000 | $4.98 | $49,800.00 | |
| 7/20/2015 | Daniel Bradbury | Director | Sell | 10,000 | $5.32 | $53,200.00 | |
| 7/8/2015 | David L Mahoney | Director | Sell | 33,828 | $5.74 | $194,172.72 | |
| 7/1/2015 | James N Wilson | Director | Sell | 10,000 | $6.06 | $60,600.00 | |
| 6/24/2015 | Daniel Bradbury | Director | Sell | 20,000 | $6.75 | $135,000.00 | |
| 6/23/2015 | Daniel Bradbury | Director | Sell | 10,000 | $6.92 | $69,200.00 | |
| 6/2/2015 | James N Wilson | Director | Sell | 10,000 | $6.13 | $61,300.00 | |
| 3/24/2015 | Patrick G Enright | Director | Sell | 1,089,745 | $5.75 | $6,266,033.75 | |
| 3/19/2015 | Joseph C Cook Jr | Director | Sell | 77,200 | $5.22 | $402,984.00 | |
| 6/11/2014 | G Leonard Baker Jr | Director | Buy | 103,386 | $2.32 | $239,855.52 | |
| 5/13/2014 | Joseph Cook, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | |
| 5/12/2014 | Daniel Bradbury | Director | Buy | 138,925 | $1.80 | $250,065.00 | |
| 5/9/2014 | G Leonard Baker, Jr. | Director | Buy | 100,000 | $1.84 | $184,000.00 | |
| 5/2/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.11 | $1,027,500.00 | |
| 4/1/2014 | Patrick Enright | Director | Sell | 250,000 | $4.28 | $1,070,000.00 | |
| 3/7/2014 | Longitude Venture Partners L.P | Director | Sell | 250,000 | $4.00 | $1,000,000.00 | |
| 3/14/2013 | Joseph L Turner | Director | Buy | 10,000 | $2.01 | $20,100.00 | |
| 12/5/2012 | G Leonard Baker Jr | Director | Buy | 87,131 | $1.46 | $127,211.26 | |
| 11/23/2012 | Daniel Bradbury | Director | Buy | 179,000 | $1.39 | $248,810.00 | |
| 11/7/2012 | G Leonard Baker Jr | Director | Buy | 300,000 | $1.83 | $549,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Corcept Therapeutics Incorporated (NASDAQ:CORT)
Latest Headlines for Corcept Therapeutics Incorporated (NASDAQ:CORT)
| Source: |
|
| Date | Headline |
|---|
 | 4 Biotech Stocks That Show Promise on Sustainable Growth
finance.yahoo.com - September 14 at 6:15 PM |
 | Reviewing Corcept Therapeutics (CORT) & Cambrex Corporation (CBM)
www.americanbankingnews.com - September 11 at 4:10 PM |
| Corcept Therapeutics Incorporated (CORT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 2:50 PM |
| Corcept Therapeutics Incorporated (CORT) PT Raised to $24.00
www.americanbankingnews.com - September 8 at 12:02 PM |
| Stifel Nicolaus Initiates Coverage on Corcept Therapeutics Incorporated (CORT)
www.americanbankingnews.com - August 31 at 12:34 PM |
 | Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe
www.nasdaq.com - August 30 at 6:29 PM |
| Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe
finance.yahoo.com - August 30 at 6:28 PM |
| Top Ranked Momentum Stocks to Buy for August 29th
finance.yahoo.com - August 29 at 5:52 PM |
| Cramer's lightning round: I know I'm alone here, but I still like the airlines
finance.yahoo.com - August 28 at 10:21 PM |
| Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
finance.yahoo.com - August 25 at 3:34 PM |
| Mylan and Otsuka Ink Agreement to Commercialize Deltyba
finance.yahoo.com - August 25 at 3:34 PM |
| Corcept Therapeutics Incorporated (CORT) Given a $18.00 Price Target at Piper Jaffray Companies
www.americanbankingnews.com - August 24 at 6:28 PM |
| Aegerion Pharmaceuticals (AEGR) vs. Corcept Therapeutics (CORT) Financial Survey
www.americanbankingnews.com - August 21 at 10:26 AM |
| Corcept Therapeutics Incorporated (CORT) Upgraded by BidaskClub to Strong-Buy
www.americanbankingnews.com - August 19 at 12:24 PM |
| Today's Research Reports on Trending Tickers: Corcept Therapeutics Inc. and Opko Health Inc.
finance.yahoo.com - August 18 at 5:27 PM |
| Three Stocks Breaking Out - Nasdaq
www.nasdaq.com - August 18 at 4:45 AM |
| Three Stocks Breaking Out
finance.yahoo.com - August 16 at 5:50 PM |
| Three Breakouts, And One Possible Breakdown In Cummins
finance.yahoo.com - August 16 at 5:50 PM |
| Corcept Therapeutics Incorporated (CORT) Expected to Post Earnings of $0.14 Per Share
www.americanbankingnews.com - August 16 at 6:30 AM |
| Corcept Therapeutics Incorporated (CORT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 15 at 6:32 PM |
| Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge - Nasdaq
www.nasdaq.com - August 14 at 5:49 PM |
| Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge
finance.yahoo.com - August 14 at 5:49 PM |
| Can The Uptrend Continue for Corcept Therapeutics (CORT)?
finance.yahoo.com - August 9 at 5:35 PM |
| Top Ranked Momentum Stocks to Buy for August 7th - Yahoo Finance
finance.yahoo.com - August 9 at 3:10 AM |
| Corcept Therapeutics Incorporated (CORT) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - August 6 at 11:56 AM |
 | Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 4:24 AM |
 | Why Corcept Therapeutics Incorporated Stock Surged Higher Today - Motley Fool
www.fool.com - August 3 at 4:24 AM |
| Edited Transcript of CORT earnings conference call or presentation 1-Aug-17 9:00pm GMT
finance.yahoo.com - August 2 at 11:20 PM |
| Why Corcept Therapeutics Incorporated Stock Surged Higher Today
www.fool.com - August 2 at 7:32 PM |
| Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised
finance.yahoo.com - August 2 at 6:15 PM |
| How These 2 Biotechs Defied The Downtrend To Hit Fresh Highs
finance.yahoo.com - August 2 at 6:15 PM |
| Corcept Therapeutics Incorporated (NASDAQ:CORT) Issues Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - August 2 at 2:42 PM |
 | FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount
www.rttnews.com - August 2 at 4:07 AM |
| Corcept beats 2Q profit forecasts
finance.yahoo.com - August 1 at 11:05 PM |
| Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update
finance.yahoo.com - August 1 at 6:05 PM |
| ETFs with exposure to Corcept Therapeutics, Inc. : August 1, 2017
finance.yahoo.com - August 1 at 6:05 PM |
| 3 Under-the-Radar Stocks in the Healthcare Sector
finance.yahoo.com - July 26 at 6:01 PM |
| Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference ... - Nasdaq
www.nasdaq.com - July 25 at 5:22 PM |
| Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
finance.yahoo.com - July 25 at 5:22 PM |
| Corcept Therapeutics Incorporated (CORT) to Release Earnings on Monday
www.americanbankingnews.com - July 24 at 8:41 AM |
| Corcept Therapeutics Incorporated (CORT) Upgraded to "Strong-Buy" at Zacks Investment Research
www.americanbankingnews.com - July 23 at 11:50 PM |
| David L. Mahoney Sells 6,091 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 21 at 7:51 PM |
| Corcept Therapeutics Incorporated (CORT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 21 at 6:50 PM |
| Corcept Therapeutics Incorporated (CORT) Director Sells $287,575.00 in Stock
www.americanbankingnews.com - July 20 at 10:24 PM |
| Is It Too Late to Get In on This Millionaire-Maker Stock?
www.fool.com - July 16 at 6:42 AM |
| David L. Mahoney Sells 6,994 Shares of Corcept Therapeutics Incorporated (CORT) Stock
www.americanbankingnews.com - July 14 at 8:46 PM |
| Corcept Therapeutics Incorporated (NASDAQ:CORT) Director David L. Mahoney Sells 6,510 Shares
www.americanbankingnews.com - July 14 at 8:46 PM |
 | Corcept Therapeutics Focuses on Korlym's Label Expansion
www.zacks.com - July 13 at 6:31 PM |
| Corcept Therapeutics Focuses on Korlym's Label Expansion
finance.yahoo.com - July 13 at 6:30 PM |
| ETFs with exposure to Corcept Therapeutics, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 6:06 PM |
Corcept Therapeutics Incorporated (CORT) Chart for Wednesday, September, 20, 2017
